Bayer v Teva: Drug formulation patent found “the result of standard and routine considerations” ([2021] EWHC 2690 (Pat))
http://ipkitten.blogspot.com/2021/11/bayer-v-teva-drug-formulation-patent.html The recent decision of the English High Court in Bayer v Teva [2021] EWHC 2690 (Pat) is another example in which the UK courts have found a pharmaceutical invention to be the obvious outcome of routine drug development. In the Supreme Court decision Actavis v ICOS the court found a drug dose selection obvious in... Continue reading